Abstract Body

This is an exciting time for tuberculosis drug development with a number of clinical trials reporting (REFAQUIN, OFLOTUB, REMoxTB). The challenge facing drug development is illustrated by the flouroquinolones trials to prove the promising results in Phase 2 regimens. It is time that we review drug development methodologies critically. The dizzying number of potential dosages and combinations of novel, established and repurposed agents requires rapid pre-selection of the most promising regimens from pre-clinical and early phase clinical trials. These regimens must be optimized at low cost to select the right regimen for a pivotal registration trial. A combination of innovative animal models, early clinical trial designs that gathers safety and DDI data as early as possible and efficacy outcome measurements in phase II studies that do not only look for bacillary clearance from sputum but also for relapse is needed. This presentation will review the different approaches that are currently under consideration.

viewer?TAG_ACTION=SECURE_FILE_DOWNLOAD&V